Ultrasound sensitive eLiposomes containing doxorubicin for drug targeting therapy

Area of Science:

• Nanotechnology
• Drug Delivery Systems
• Biomedical Engineering

Background:

• Doxorubicin (Dox) is a widely used chemotherapy drug with significant cardiotoxicity.
• Current drug delivery methods for Dox often lead to systemic toxicity and limited local efficacy.
• Ultrasound-sensitive nanocarriers offer a promising approach to improve Dox delivery and reduce side effects.

Purpose of the Study:

• To develop and characterize a novel ultrasound-sensitive nanocarrier for doxorubicin delivery.
• To evaluate the controlled release of doxorubicin from the nanocarrier upon ultrasound exposure.
• To assess the efficacy of the nanocarrier in delivering doxorubicin to cancer cells and reducing cardiotoxicity.

Main Methods:

• Fabrication of emulsion liposomes (eLiposomes) encapsulating doxorubicin (Dox) within a perfluoropentane nanodroplet and DPPC liposome.
• Insonation of eLiposomes with low-intensity ultrasound at various frequencies (20 kHz, 1.0 MHz, 3.0 MHz) to induce Dox release.
• In vitro assessment of Dox release kinetics and cellular uptake in HeLa tumor cells using confocal microscopy.
• Evaluation of Dox delivery to the cell cytosol upon ultrasound stimulation.

Main Results:

• The developed eLiposomes (eLipoDox) successfully encapsulated doxorubicin.
• Doxorubicin release from eLipoDox was demonstrated upon ultrasound insonation, with greater release observed at 20 kHz compared to higher frequencies.
• Confocal imaging confirmed effective delivery of Dox to the cytosol of HeLa cells following ultrasound exposure.
• The nanocarrier system showed controlled drug release and targeted delivery to cancer cells.

Conclusions:

• Emulsion liposomes (eLiposomes) represent a novel and effective nanocarrier for doxorubicin.
• Ultrasound-triggered doxorubicin release from eLipoDox enables controlled drug delivery to cancer cells.
• This innovative drug delivery system holds potential for enhanced ultrasound therapy and tumor treatment.
• The eLiposome system may reduce doxorubicin-induced cardiotoxicity, improving patient outcomes.